US sales of branded drug MiraLAX were $200 million in the past year.
Mira Awwad, Globes[online] (7 Oct 09)


Perrigo Company (Nasdaq:PRGO; TASE:PRGO) has obtained final US Food and Drug Administration (FDA) approval for the company's generic over-the-counter laxative powder, Polyethylene Glycol 3350, and will begin shipments immediately.
Perrigo will market the laxative under store brand labels. The product is comparable to Schering-Plough Corporation's (NYSE: SGP) MiraLAX, which had an estimated $200 million in US sales in the 12 months through August 2009.